Business
Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
WIXOM, Mich., March 26, 2026--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025.
About this update from Rockwell Medical, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/38e78884118571e7dcfcc8e53050edd5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c1Qa30p54HEaDezLMmMRTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/business-wire.com/38e78884118571e7dcfcc8e53050edd5","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively.","length":103,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025.","length":91,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Generated 21% in gross margin for the fourth quarter 2025, representing one of the strongest quarters for gross margin in the Company's history and a meaningful improvement over 15% gross margin for the same period in 2024.","length":227,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported $2.3 million in cash flow from operating activities in the fourth quarter 2025, which increased the Company's cash position at year-end 2025 to $25.0 million.","length":171,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":592,"olType":false},{"type":"text","content":"WIXOM, Mich., March 26, 2026--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and twelve months ended December 31, 2025.","length":370,"tagName":"p"},{"type":"text","content":""2025 was a year of transition for Rockwell Medical. We successfully navigated changes in our customer base, purchase volumes, and distribution footprint, all while maintaining profitability on an Adjusted EBITDA basis for the second consecutive year," said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. "We made significant changes internally to further align our infrastructure with demand. As a result, our gross marg...